Examining the tumor microenvironment with patient-derived xenografts (PDX)
Representing clonal diversity in the tumor microenvironment of a xenograft model improves the translatability of a study and is an important component of personalized medicine. Patients willing to contribute a portion of their biopsies for research purposes are contributing not only cancer cells, but the surrounding ecosystem, giving researchers insight into the supporting role of the stroma and extracellular matrix in the development of their disease.
While a therapy might target the cells collected in a needle biopsy, other more aggressive phenotypes in a tumor may remain undetected, potentially displaying resistance to a therapy and metastasizing to create a more invasive tumor, leading to poor clinical outcomes.
The Future of PDX
 Sun XX, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin. 2015;36:1219–27.
 Mehraj U, et al. Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications. Seminars in Cancer Biology, 2022, https://doi.org/10.1016/j.semcancer.2022.03.008
 Echeverria GV, et al. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med. 2019 Apr 17;11(488):eaav0936. doi: 10.1126/scitranslmed.aav0936.
 Cassidy JW, et al. Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. Cancer Res 1 August 2015; 75 (15): 2963–2968. https://doi.org/10.1158/0008-5472.CAN-15-0727